Name: HCW BIOLOGICS INC (HCWB) Stock
Brand: HCW BIOLOGICS INC
Rating: 3 (3 reviews)

HCWB Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: HCW Biologics Inc.

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

8 days ago - By: HCW Biologics Inc.

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

9 days ago - By: Benzinga - Mentions: AIM NUVL GLMD VTGN ...

12 Health Care Stocks Moving In Monday's After-Market Session

9 days ago - By: Benzinga - Mentions: JAZZ AEMD BYSI ZYME ...

12 Health Care Stocks Moving In Monday's Pre-Market Session

12 days ago - By: HCW Biologics Inc.

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

3 months ago - By: The Motley Fool

Hcw Biologics Revenue Plunges 98 Percent

19 days ago - By: HCW Biologics Inc.

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

a month ago - By: HCW Biologics Inc.

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

a month ago - By: HCW Biologics Inc.

HCW Biologics to Participate in the 2025 Maxim Growth Summit

a month ago - By: HCW Biologics Inc.

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

2 months ago - By: HCW Biologics Inc.

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

2 months ago - By: HCW Biologics Inc.

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

2 months ago - By: HCW Biologics Inc.

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

3 months ago - By: HCW Biologics Inc.

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

3 months ago - By: HCW Biologics Inc.

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

3 months ago - By: HCW Biologics Inc.

HCW BIOLOGICS INC (HCWB) Stock News

HCWB Latest News, Press Relases and Analysis

HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Monday's Pre-Market Session

HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results

Hcw Biologics Revenue Plunges 98 Percent

HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment

HCW Biologics to Participate in the 2025 Maxim Growth Summit

HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer

HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program

HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing

HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development

HCW Biologics Reports Positive Results from Non-Human Primate Study for Its Proprietary Second-Generation T-Cell Engager Program

HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results